Hydroxychloroquine (HCQ) belongs to the group of antimalarial agents, which recognition of its benefit in other diseases except malaria dates back to 1894, when Payne reported that quinine was effective in cutaneous lupus \[[@CR1]\]. Since then, therapeutic effects of antimalarial agents were shown in a myriad of other diseases and the evidence for its potential benefit continues to grow.

The first use of quinine as a drug is traditionally attributed to the Incan descendents in Peru, who cured the countess of Chinchon from a febrile illness with a mysterious bark powder in 1630 \[[@CR2], [@CR3]\]. Hundreds of years later, the alkaloids from the bark were extracted when chloroquine was one of a large series of 4-aminoquinolines which were investigated, beginning in 1943, as part of the extensive cooperative program of antimalarial research in the USA during World War II when thousands of compounds were synthesized and tested for activity. Chloroquine eventually proved most promising and was released for field trial. When hostilities ceased, it was discovered that the compound had been synthesized and studied as early as 1934 by the Germans but rejected because of toxicity in avian models.

During the Second World War, millions of soldiers took antimalarial prophylaxis, and the observation that antimalarial improved the soldiers' rashes and inflammatory arthritis led to the first trial that showed the efficacy of antimalarials in systemic lupus erythematosus (SLE) \[[@CR4]\]. Since then, the role of antimalarials in rheumatic diseases was established and today its use is widespread in SLE and in rheumatoid arthritis (RA) \[[@CR5]--[@CR7]\]. The synthetic form of HCQ was introduced in 1955 and differs from chloroquine only by a hydroxyl group, decreasing its toxicity while conserving its efficacy.

Hydroxychloroquine has numerous known immunomodulatory effects \[[@CR8]\], but its specific mechanism in individual diseases is not clear. The major proposed mechanisms of action of antimalarials on the immune system include: (1) interference with lysosomal acidification and inhibition of proteolysis, chemotaxis, phagocytosis, and antigen presentation \[[@CR9], [@CR10]\]; (2) decreasing macrophage-mediated cytokine production, especially interleukin (IL)-1 and IL-6 \[[@CR11]\]; (3) inhibition of phospholipase A2 and thereby antagonizing the effects of prostaglandins \[[@CR12], [@CR13]\]; (4) absorption and blocking of UV light cutaneous reactions \[[@CR14]\]; (5) binding and stabilizing DNA \[[@CR15]\]; (6) inhibition of T and B-cell receptors calcium signaling \[[@CR16]\]; and (7) inhibition of matrix metalloproteinases \[[@CR17]\]. It was recently recognized that HCQ also inhibits toll-like receptors signaling \[[@CR18]\], highlighting a new and important effect, which might play a part in numerous pathways and may contribute to our understanding of its usefulness in many autoimmune and other diseases. The various major known immunomodulatory mechanisms of HCQ is schematically drawn in Fig. [1](#Fig1){ref-type="fig"}. Fig. 1The various inhibitory and immunomodulatory effects of HCQ are schematically drawn. *PLA2* phospholipase A2, *IL* interleukin, *TLR* toll like receptor, *UV* ultraviolet

In addition to its established efficacy in SLE and RA, antimalarials were also found to be beneficial in other rheumatic and skin diseases, including palindromic rheumatism \[[@CR19]\], eosinophilic fasciitis \[[@CR20]\], dermatomyositis \[[@CR21]\], Sjögren's syndrome \[[@CR22]\], porphyria cutanea tarda \[[@CR23], [@CR24]\], polymorphous light eruption \[[@CR25]\], granuloma annulare \[[@CR26]\], lichen planus \[[@CR27]\], lupus panniculitis \[[@CR28]\], and discoid lupus \[[@CR29]\]. The traditional indications for the use of HCQ are summarized in Table [1](#Tab1){ref-type="table"}. Table 1Traditional indications and doses for the use of hydroxychloroquineIndicationDoseStudyMalaria (acute)800 mg followed by 400 mg at 6, 24, and 48 hCDC guidelines\[[@CR111]\]Rheumatoid arthritis400--600 mg/dayClark et al. \[[@CR5]\]SLE200--400 mg/dayTsakonas et al. \[[@CR7]\], Molad et al. \[[@CR6]\]Palindromic rheumatism200--400 mg/dayYoussef et al. \[[@CR19]\]Eosinophilic fasciitis400 mg/dayLakhanpal et al. \[[@CR20]\]Dermatomyositis400 mg/dayWoo et al. \[[@CR21]\]Sjögren's syndrome6--7 mg/kg/dayFox et al. \[[@CR22]\]Porphyria cutanea tarda250--500 mg/weekAshton et al. \[[@CR23]\], Valls et al. \[[@CR24]\]Polymorphous light eruption200--400 mg/dayMurphy et al. \[[@CR25]\]Granuloma annulare2--9 mg/gk/dayCannistraci et al. \[[@CR26]\]Lichen planus200--400 mg/dayEisen \[[@CR27]\]Lupus panniculitis200--400 mg/dayChung et al. \[[@CR28]\]Discoid lupus400 mg/dayJessop et al. \[[@CR29]\]*SLE* systemic lupus erythematosus

Recently, antimalarials were shown to have potential beneficial effects in many other diseases, including diseases of the immune, cardiovascular, and hematological systems, as well as malignant and infectious diseases other than malaria. Here, we review the current evidence for novel applications of the antimalarials, mainly chloroquine and HCQ.

Antimicrobial Effects {#Sec1}
=====================

In addition to its antimalarial effect, HCQ was found to be effective against bacterial and viral infections. Its antibacterial and antiviral effects are attributed to the alkalinization of intracellular acidic organelles infected by bacteria and to the inhibition of entry steps and viral proteins glycosylation \[[@CR30]\]. The most recognized antibacterial effect of HCQ is in *Coxiella burnetii* infections, where the treatment of choice for chronic Q-fever endocarditis consists of HCQ together with doxycycline for 18--36 months.

In the human immunodeficiency virus (HIV), HCQ was shown to inhibit virus replication in T cells, by inhibiting the surface envelope glycoprotein 120 \[[@CR31]--[@CR34]\]. This anti-HIV mechanism lacks cross-resistance with other antiretroviral drugs and was novel in the armamentarium of anti-HIV drugs. Paton et al. \[[@CR35]\] showed that combined treatment with HCQ, hydroxyurea, and didanosine in antiretroviral naïve HIV patients with low viral load, decreased viral replication, and increased the CD4 count. However, in the current era of the highly active anti-retroviral therapy for HIV, the use of non anti-retroviral drugs such as HCQ is probably redundant.

Human corona virus (hCoV) caused a near pandemic of severe acute respiratory syndrome in 2002--2003. To date, no specific antiviral drugs for the prevention or treatment of hCoV infection are available. Recently, chloroquine was shown to inhibit the replication and spread of corona virus in vitro \[[@CR36], [@CR37]\] and to prevent infection with hCoV in newborn mice \[[@CR38]\], showing promise as a potential therapy of this resistant virus.

Metabolic and Cardiovascular Effects {#Sec2}
====================================

The hypoglycemic effect of chloroquine was first demonstrated in a patient with insulin resistance in 1984 \[[@CR39]\]. Later on, a clinical trial of non-insulin dependent diabetic patients who were treated with a short course of chloroquine exhibited a significant improvement in glucose tolerance in these patients \[[@CR40]\]. When HCQ was combined with insulin for 6 months, the glycated hemoglobin decreased significantly compared to placebo, and the insulin dose had to be reduced by 30% in the HCQ group \[[@CR41]\]. In another study, diabetic patients who did not respond to sulfonylurea were successfully treated with HCQ and their glycated hemoglobin was reduced by 1% \[[@CR42]\]. The presumed anti-diabetic mechanism of chloroquine is by a decrease in the insulin clearance and degradation rate and an increase in the secretion of C-peptide \[[@CR43], [@CR44]\]. Although HCQ was shown to have hypoglycemic effects, it should be noted the current treatment options for diabetes mellitus (DM) are varied and effective, so a role for antimalarials in diabetes treatment is unlikely.

The use of HCQ may also be beneficial for reducing cardiovascular risk by improving glycemic control in RA and SLE patients; Shojania et al. \[[@CR45]\] described a case of induction of hypoglycemia in a patient with DM and polyarthritis treated with HCQ. Later, in a cohort of patients with SLE or RA, treatment with HCQ was associated with lower levels of fasting blood glucose \[[@CR46]\] and significantly lowered the risk to develop DM in RA patients \[[@CR47]\]. It was recently shown that HCQ significantly reduces glycosylated hemoglobin in diabetes patients \[[@CR48]\]. This observed association between HCQ treatment and lower risk of DM in rheumatic patients needs further clinical and pharmacological studies to assess HCQ's effect on blood sugar before becoming common clinical practice.

Hydroxychloroquine was also shown to have a favorable effect on lipid profile in patients with rheumatic diseases. Wallace et al. \[[@CR49]\] showed that in RA and SLE, treatment with HCQ lowered the levels of cholesterol, triglycerides and LDL, irrespective of concomitant steroid administration, diet, or weight. Later studies confirmed this observation and suggested that this should be taken into account in rheumatic patients with significant cardiovascular risk factors and in ameliorating the adverse effects of corticosteroid therapy on lipid profile \[[@CR50]--[@CR52]\]. However, a different study in Chinese SLE patients did not show significant effect on serum lipid profile, but these patients had mild or absent disease-activity and used low corticosteroid dose \[[@CR53]\]. Of note, in addition to its metabolic effects on blood sugar and lipids, HCQ was recently also shown to improve endothelial function and to protect against thrombovascular events in lupus patients \[[@CR54]--[@CR56]\].

Antithrombotic Effects {#Sec3}
======================

Approximately 30 years ago, HCQ was shown to prevent thromboembolic events in patients going total hip replacement \[[@CR57]\]. The mechanism was unknown at the time, but it was later shown that HCQ inhibits platelet aggregation and the release of arachidonic acid from stimulated platelets \[[@CR58]\]. Treatment with HCQ was also shown to be protective against thrombosis in lupus patients with antiphospholipid syndrome (APS) \[[@CR59], [@CR60]\] and to reduce the risk of plaque formation in these patients \[[@CR61]\]. Furthermore, HCQ seemed to be protective against thrombus formation in a group of anti-phospholipid (aPL) antibodies carriers without lupus \[[@CR62]\].

The antithrombotic mechanism of HCQ in APS is not completely understood, but some novel observations were recently made; Edwards et al. \[[@CR63]\] found that HCQ decrease thrombus size and shortens the time to thrombus clearance in mice injected with human aPL antibodies. More recently, Espinola et al. \[[@CR64]\] showed that HCQ inhibits platelets activation by aPL antibodies and Rand et al. showed that HCQ significantly reduces the binding of aPL-beta2-glycoprotein I complexes to phospholipid surfaces and also protects against the disruption of the potent anticoagulant annexin A5 by aPL antibodies in vitro and in patients' plasma \[[@CR65], [@CR66]\]. These finding suggest that HCQ should be an integral part of the treatment of APS, especially in patients with concomitant SLE.

Antineoplastic Effects {#Sec4}
======================

The antineoplastic effect of antimalarials was first observed when a program of chloroquine prophylaxis against malaria in Tanzania was associated with a reduction in the incidence of Burkitt lymphoma \[[@CR67]\]. Later, chloroquine was shown to prevent spontaneous lymphoma development in mice models of human Burkitt lymphoma and ataxia telangiectasia, through the suppression of autophagy and an induction of p53-dependent cell death pathway \[[@CR68]\]. Hydroxychloroquine was also shown to induce apoptosis of malignant B-cells from patients with chronic lymphocytic leukemia (CLL), through the activation of caspase-3 and modulation of Bcl-2/bax ratio \[[@CR69], [@CR70]\]. Recently, a biodegradable nanoparticle drug delivery system loaded with HCQ was shown to produce a strong apoptotic effect on B-CLL cells in vitro \[[@CR71]\].

Except for its effect on hematological malignancies, HCQ was also shown to have antineoplastic effects on solid tumors: (1) An anti breast-cancer effect was shown by demonstration of its antiproliferative effect on the human breast tumor cell models MCF-7 and Bcap-37 \[[@CR72]--[@CR74]\]. (2) An antiproliferative effect on mouse colon cancer cell line was shown, as well as a reduction in tumor volume in vivo with chloroquine treatment \[[@CR75]\]. Chloroquine was also shown to potentiate the antiproliferative effect of 5-fluorouracil on the human colorectal cell line HT-29 \[[@CR76]\]. (3) Chloroquine was shown to inhibit growth and induce cell death of A549 lung cancer cells \[[@CR77]\]. (4) In a randomized, double-blind, placebo-controlled trial, patients with glioblastoma multiforme who were treated with chloroquine had a much better survival rate compared with non-treated patients \[[@CR78]\].

In addition to its independent antineoplastic effects, chloroquine was shown to effectively sensitize cancer cells to radiation and chemotherapy, without enhancing normal cells vulnerability \[[@CR79], [@CR80]\]. Although these preliminary studies look promising, the potential role for antimalarials in the treatment paradigm of malignancies still remains to be established.

Additional Effects {#Sec5}
==================

In addition to its immunomodulatory effects described above, HCQ was also shown to inhibit the T cell response to foreign minor and major histocompatibility antigens and therefore inhibit the development of graft versus host disease (GVHD) in mice \[[@CR81]\]. A phase II trial in patients who received bone marrow transplantation, showed better GVHD free survival and lower incidence of high-grade GVHD in patients who were treated with HCQ in addition to the traditional immunosuppressive drugs \[[@CR82]\]. However, a phase III trial failed to exhibit additional benefit in GVHD prevention when HCQ was added to monotherpay with cyclosporine A \[[@CR83]\].

Additional beneficial effects of HCQ were also shown anecdotally in other diseases: (1) Hydroxychloroquine was shown to be very effective in Kikuchi--Fujimoto disease, a benign disease characterized by lymphadenopathy and fever, usually occurring in young women \[[@CR84], [@CR85]\]. (2) Skeletal and metabolic effects of sarcoidosis were successfully treated with HCQ in patients who were not candidates for glucocorticoid treatment \[[@CR86]--[@CR88]\]. (3) Hydroxychloroquine enabled steroid cessation in patients with subglottic stenosis who were steroid dependent due to edema and granulation tissue \[[@CR89]\]. (4) Hydroxychloroquine in combination with azathioprine prompted a major recovery in a patient with sensory neuropathy syndrome \[[@CR90]\]. (5) Exposure to HCQ during pregnancy in mothers with SLE who carried anti-Ro/La antibodies was associated with a decreased risk of fetal development of cardiac neonatal lupus, compared to mothers who were not treated with HCQ \[[@CR91], [@CR92]\]. (6) Hydroxychloroquine was shown to enhance the production of hemoglobin F, showing a therapeutic potential for hemoglobinopathies \[[@CR93]\].

Antimalarials Toxicity {#Sec6}
======================

Antimalarials are contraindicated in known hypersensitivity and in patients with a history of retinopathy. Taken in proper doses, chloroquine is an extraordinarily safe drug; however, its safety margin is narrow, and a single dose of 30 mg/kg may be fatal \[[@CR94]\]. Caution should be used in patients with neuromuscular disorders such as myasthenia gravis and in patients with psychotic disorders. Patients with glucose-6-phosphate deficiency should be carefully monitored for hemolysis, although this is extremely rare in therapeutic doses.

Acute chloroquine toxicity is encountered most frequently when therapeutic or high doses are administered too rapidly by parenteral routes. Toxic manifestations relate primarily to the cardiovascular system and the central nervous system (CNS). Cardiovascular effects include hypotension, vasodilation, suppressed myocardial function, cardiac arrhythmias, and eventual cardiac arrest. CNS side-effects may include confusion, convulsions, and coma. Doses of chloroquine used for oral therapy of acute malarial attack and for rheumatic and skin diseases may cause GI upset, headache, visual disturbances, urticaria, and pruritus. Prolonged use may occasionally cause headache, blurred vision, diplopia, confusion, convulsions, lichenoid skin eruptions, bleaching of hair, widening of the QRS interval, and T wave abnormalities. These complications are rare and usually disappear soon after the drug is withheld. Rare instances of hemolysis and blood dyscrasias have been reported \[[@CR95]\]. Chloroquine may also cause discoloration of nail beds and mucous membranes \[[@CR96]\].

Irreversible retinopathy and ototoxicity can result from high daily doses (\>250 mg) of chloroquine or HCQ that lead to cumulative total doses of more than 1 g of base per kilogram body weight \[[@CR97]--[@CR99]\]. Retinopathy presumably is related to drug accumulation in melanin-rich tissues and can be avoided if the daily dose is 250 mg or less. Prolonged therapy with high doses can also cause toxic myopathy, cardiopathy, and peripheral neuropathy \[[@CR100]--[@CR103]\]; these reactions improve if the drug is withdrawn promptly \[[@CR104]\].

Hydroxychloroquine crosses the placenta as fetus levels were shown to be equivalent to maternal levels \[[@CR105]\]. However, no fetal toxicity was evident in subsequent studies and no congenital abnormalities were seen in pregnant patients treated with HCQ during the first trimester of pregnancy \[[@CR106], [@CR107]\]. During lactation, the amount of HCQ transferred to children seems very low and does not confer a risk of toxicity to the child \[[@CR108], [@CR109]\]. Accordingly, continuation of HCQ use during pregnancy is recommended and there's no evidence to advice against breastfeeding during treatment \[[@CR110]\]. A summary of antimalarials toxicity and main adverse effects is presented in Table [2](#Tab2){ref-type="table"}. Table 2Main adverse effects of chloroquine and HCQ treatmentTypeOcularRetinopathy (early changes reversible, may progress despite discontinuation if advanced), blurred vision, corneal changes/depositsNeuromuscular and skeletalMyopathy, palsy, or neuromyopathy leading to progressive weakness and atrophy of proximal muscle groups (may be associated with mild sensory changes, loss of deep tendon reflexes, and abnormal nerve conduction)CardiovascularCardiomyopathy (rare, relationship to HCQ unclear)Central nervous systemAtaxia, dizziness, emotional changes, headache, irritability, lassitude, nervousness, nightmares, psychosis, seizure, vertigoGastrointestinalAbdominal cramping, anorexia, nausea, vomiting, diarrhea, abnormal liver functionCutaneousAlopecia, angioedema, bleaching of hair, pigmentation changes (skin and mucosal; black-blue color), rash, pruritusOticDeafness, tinnitusRespiratoryBronchospasm, respiratory failure (myopathy-related)HematologicalAgranulocytosis, aplastic anemia, hemolysis (in patients with glucose-6-phosphate deficiency), leukopenia, thrombocytopeniaOtherExacerbation of psoriasis

In conclusion, since the first use of antimalarial agents nearly a century ago, their effects on diseases in nearly all major branches of medicine have been increasingly recognized, including the fields of immunology, oncology, hematology, dermatology, cardiology, and infectious diseases. A summary of the effects of antimalarials is shown in Table [3](#Tab3){ref-type="table"}. To date, antimalarials have an established role in treatment of SLE, RA, chronic Q fever, and various skin diseases. They may also have a role in the treatment of antiphospholipid syndrome. There are currently many ongoing clinical trials studying the effects of antimalarials in other diseases, such as malignant neoplasms of the lung, breast, prostate, pancreas and colon, melanoma, renal cell carcinoma, CLL, multiple myeloma, influenza, HIV infection, osteoarthritis, and the metabolic syndrome, as can be seen by browsing the website [clinicaltrials.gov](http://clinicaltrials.gov). The mechanism of action of HCQ and its effectiveness in these diseases and in other potential conditions still remains to be demonstrated in the future. Table 3A summary of the effects of antimalarials in various conditionsEffectDisease/stateMechanismAntimicrobialChronic Q fever endocarditisAlkalinization of phagosomeHuman immunodeficiency virusInhibition of virus replicationHuman corona virusInhibition of replicationMetabolic and cardiovascularHypoglycemic in diabetes mellitusDecreasing insulin clearance and increasing secretion of C-peptideImproves lipid profile in SLE and RA and in steroid useImprove endothelial functionAntithromboticPrevention of thromboembolism in immobilized patientsInhibition of platelet aggregation and arachidonic acid releasePrevention of thrombosis in antiphospholipid syndromeInhibition of platelets activation by aPL antibodies, reducing binding of aPL-beta2-GPI to antiphospholipids and disruption of annexin A5 by aPL antibodiesAntineoplasticPrevention of lymphoma in miceInduction of p53-dependentcell deathInduction of apoptosis in CLL cellsActivation of caspase-3Solid tumors: e.g., breast, colon, glioblastoma multiforme, lungSensitization of cancer cells to radiation and chemotherapyOtherPrevention of GVHD diseaseInhibition of T cell response to MHC antigensKikuchi--Fujimoto diseaseSarcoidosisSubglottic stenosisSensory neuropathyDecreases risk of fetal cardiac lupusWhere known, the mechanism is described*aPL* antiphospholipid, *GP* glycoprotein, *CLL* chronic lymphocytic leukemia, *GVHD* graft versus host disease, *MHC* major histocompatibility complex
